Clinical Trials Browser

Interventional × lenvatinib × Gynecologic × Clear all

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

Phase 2 Recruiting

Vulvar Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04977453 2026-03-17

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

Endometrial Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Endometrial Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2 Not yet recruiting

Adenocarcinoma, Uterine Cervical Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05296512 2025-12-16

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Phase 2 Active not recruiting

Ovarian Clear Cell Carcinoma

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Phase 3 Not yet recruiting

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Phase 2 Not yet recruiting

Advanced Endometrial Cancer

NCT04865289 2025-12-02

LEAP-001

Phase 3 Completed

130 enrolled 24 charts

Endometrial Neoplasms

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT07177716 2025-09-17

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

Phase 2/3 Not yet recruiting

Uterine Cervical Neoplasms

NCT05903833 2025-09-09

PIERCE

Phase 2 Recruiting

Vulvar Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Phase 2 Active not recruiting

High Grade Fallopian Tube Serous Adenocarcinoma

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01111461 2023-06-22

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Phase 2 Completed

133 enrolled 16 charts

Endometrial Neoplasms

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1/2 Terminated

7 enrolled 6 charts

Ovarian Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

NCT02788708 2022-09-19

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Unknown

Carcinoma, Ovarian Epithelial

NCT03006887 2021-05-20

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1 Completed

6 enrolled 27 charts

GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms

NCT04444193 2020-06-23

Dulect2020-2

Phase NA Unknown

Endometrial Neoplasms

NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

Phase 2 Withdrawn

Endometrial Neoplasms